Neurocrine Biosciences (NASDAQ:NBIX) PT Raised to $128.00
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price raised by Royal Bank of Canada from $123.00 to $128.00 in a report released on Wednesday morning, Benzinga reports. They currently have a sector perform rating on the stock. A number of other equities analysts have also recently commented on the company. Raymond James boosted […]
More Stories
Virpax Pharmaceuticals Receives Nasdaq Panel Decision, Granted Listing Continuation with Conditions
On January 6, 2025, Virpax Pharmaceuticals, Inc. announced in a Form 8-K filing that it had received a decision from...
Mangoceuticals (NASDAQ:MGRX) Enters into Securities Purchase Agreements with Institutional Investors
Dallas, Texas, January 8, 2025 – Mangoceuticals, Inc. (NASDAQ:MGRX) recently disclosed in a Form 8-K filing with the Securities and...
**MedTech Acquisition Announces Leadership Transition and Salary Investment Program**
MedTech Acquisition (OTCMKTS:MTACU) recently disclosed its current report with the Securities and Exchange Commission (SEC) dated January 4, 2025. The...
CJM Wealth Advisers Ltd. Raises Stock Holdings in The Home Depot, Inc. (NYSE:HD)
CJM Wealth Advisers Ltd. boosted its holdings in The Home Depot, Inc. (NYSE:HD – Free Report) by 4.8% during the...
Eagle Point Income (NYSE:EIC) Upgraded at B. Riley
B. Riley upgraded shares of Eagle Point Income (NYSE:EIC – Free Report) to a strong-buy rating in a research note...
Burlington Stores (NYSE:BURL) Stock Rating Upgraded by UBS Group
Burlington Stores (NYSE:BURL – Get Free Report) was upgraded by research analysts at UBS Group from a “neutral” rating to...